Jaguar Health Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Jaguar Health de 25.9% y 34.8% respectivamente, mientras que el BPA crecerá en un 66.4% al año.
Información clave
25.9%
Tasa de crecimiento de los beneficios
66.4%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 23.8% |
| Tasa de crecimiento de los ingresos | 34.8% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 19 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Nov 09Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jul 24Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
May 24Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Mar 29Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Jan 22Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
Jun 10Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
Jan 23Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment
Oct 17Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront
Aug 25Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule
Aug 19Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea
Aug 09Jaguar stock rises on license deal with SynWorld for Canalevia in China
Jun 29Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory
Mar 07Jaguar Health shares jumps 13% after pricing $15M direct offering
Jan 13Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients
Jan 11Jaguar Health leaps higher in new year
Jan 05Jaguar Health inks second Mytesi royalties agreement for $6M
Dec 23Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?
Dec 02
Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%
Nov 30Jaguar Health EPS misses by $0.10, misses on revenue
Nov 16Jaguar Health receives positive Nasdaq listing determination
Oct 29Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 22 | -20 | N/A | -25 | 1 |
| 12/31/2025 | 16 | -27 | N/A | -24 | 1 |
| 12/31/2024 | 11 | -36 | N/A | -26 | 1 |
| 9/30/2024 | 10 | -38 | -29 | -29 | N/A |
| 6/30/2024 | 10 | -36 | -29 | -29 | N/A |
| 3/31/2024 | 10 | -38 | -30 | -30 | N/A |
| 12/31/2023 | 10 | -41 | -33 | -33 | N/A |
| 9/30/2023 | 11 | -40 | -33 | -32 | N/A |
| 6/30/2023 | 11 | -44 | -34 | -34 | N/A |
| 3/31/2023 | 11 | -42 | -37 | -35 | N/A |
| 12/31/2022 | 12 | -47 | -35 | -33 | N/A |
| 9/30/2022 | 11 | -54 | -37 | -36 | N/A |
| 6/30/2022 | 8 | -54 | -38 | -37 | N/A |
| 3/31/2022 | 6 | -59 | -36 | -36 | N/A |
| 12/31/2021 | 4 | -53 | -35 | -35 | N/A |
| 9/30/2021 | 5 | -50 | -30 | -30 | N/A |
| 6/30/2021 | 7 | -46 | -24 | -24 | N/A |
| 3/31/2021 | 10 | -42 | -18 | -18 | N/A |
| 12/31/2020 | 9 | -39 | -15 | -15 | N/A |
| 9/30/2020 | 8 | -35 | -14 | -14 | N/A |
| 6/30/2020 | 7 | -39 | -20 | -20 | N/A |
| 3/31/2020 | 5 | -45 | -21 | -21 | N/A |
| 12/31/2019 | 6 | -45 | -20 | -20 | N/A |
| 9/30/2019 | 6 | -48 | -22 | -22 | N/A |
| 6/30/2019 | 6 | -43 | -16 | -16 | N/A |
| 3/31/2019 | 5 | -34 | -17 | -17 | N/A |
| 12/31/2018 | 4 | -32 | -23 | -23 | N/A |
| 9/30/2018 | 4 | -41 | -23 | -23 | N/A |
| 6/30/2018 | 4 | -30 | N/A | -23 | N/A |
| 3/31/2018 | 4 | -24 | N/A | -19 | N/A |
| 12/31/2017 | 4 | -22 | N/A | -10 | N/A |
| 9/30/2017 | 3 | -5 | N/A | -7 | N/A |
| 6/30/2017 | 2 | -14 | N/A | -17 | N/A |
| 3/31/2017 | 1 | -17 | N/A | -15 | N/A |
| 12/31/2016 | 0 | -15 | N/A | -14 | N/A |
| 12/31/2015 | 0 | 5 | N/A | 1 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que JAGX siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que JAGX siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que JAGX siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (34.8% al año) de JAGX crezcan más rápidamente que los del mercado US (9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (34.8% al año) de JAGX crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de JAGX se prevé que sea elevada dentro de 3 años.